Novartis: Bryan Garnier upgrades its rating.
(CercleFinance.com) - Bryan Garnier is upgrading its rating on Novartis from "neutral" to "buy," raising its target price from 80 Swiss francs to 90 Swiss francs, the day before the Swiss health group publishes its interim results.
Although it expects a decline in the final quarter, the broker believes that the consensus was well prepared for this by the group, it says “We actually even believe that there is room for a reassuring composition of the quarterly numbers”.
Bryan Garnier actually considers "the first signs of recovery for both Alcon and Entresto, which will no longer play as overhangs; (ii) good performance from key growth drivers like Cosentyx and good management of operational costs."
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Although it expects a decline in the final quarter, the broker believes that the consensus was well prepared for this by the group, it says “We actually even believe that there is room for a reassuring composition of the quarterly numbers”.
Bryan Garnier actually considers "the first signs of recovery for both Alcon and Entresto, which will no longer play as overhangs; (ii) good performance from key growth drivers like Cosentyx and good management of operational costs."
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.